

Whole-exome sequencing study identifies novel rare variants and genes associated with intraocular pressure and glaucoma

Xiaoyi Raymond Gao^{1,2,3,4*}, Marion Chiariglione¹, Alexander J. Arch¹

¹Department of Ophthalmology and Visual Sciences, The Ohio State University, Columbus, OH 43210, USA

²Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA

³Division of Human Genetics, The Ohio State University, Columbus, OH 43210, USA

⁴Ohio State University Physicians Inc., Columbus, OH, USA

*Correspondence should be addressed to:

Xiaoyi Raymond Gao, PhD

Department of Ophthalmology and Visual Sciences

Department of Biomedical Informatics

Division of Human Genetics

The Ohio State University

Columbus, OH 43212

USA

Phone: (614) 293-5287

Fax: (614) 293-5602

Email: raymond.gao@osumc.edu

Abstract

Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, the leading cause of irreversible blindness worldwide. IOP is also the only modifiable risk factor for glaucoma. Previous genome-wide association studies have established the contribution of common genetic variants to IOP. The role of rare variants for IOP was unknown. Using whole exome sequencing data from 454,756 participants in the UK Biobank (UKB), we conducted the largest exome-wide association study of IOP to date. In addition to confirming known IOP genes, we identified 40 novel rare-variant genes for IOP, such as *BODILI*, *ACAD10* and *HLA-B*, demonstrating the power of including and aggregating rare variants in gene discovery. About half of these IOP genes are also associated with glaucoma phenotypes in UKB and the FinnGen cohort. Six of these genes, i.e. *ADRB1*, *PTPRB*, *RPL26*, *RPL10A*, *EGLN2*, and *MTOR*, are drug targets that are either established for clinical treatment or in clinical trials. Furthermore, we constructed a rare-variant polygenic risk score and showed its significant association with glaucoma in independent subjects. We demonstrated the value of rare variants to enhance our understanding of the biological mechanisms regulating IOP, and uncovered potential novel therapeutic targets for glaucoma.

Introduction

Elevated intraocular pressure (IOP) is a major risk factor for glaucoma, the leading cause of irreversible blindness worldwide. IOP is also the only modifiable risk factor for glaucoma. Current glaucoma drugs target lowering IOP. Previous studies using directly genotyped and imputed genetic data have uncovered common and some low-frequency variants for IOP¹⁻⁶. Identifying rare variants that contribute to IOP will help uncover the biological mechanisms regulating this trait and provide improved understanding of IOP regulation and potential new therapeutic targets for managing IOP and glaucoma.

Genome-wide association studies (GWAS) have identified over 149 genetic loci associated with IOP¹⁻⁴. These loci have established the contribution of common variants to IOP. Many of these IOP loci are also associated with glaucoma^{4,5}. While these studies identified numerous loci associated with IOP, these common variants typically show small effect sizes. The role of rare variants for IOP remains to be discovered. Rare variants typically require sequencing and a large sample size to have adequate statistical power.

The UK Biobank (UKB) is a large prospective cohort of half a million adult participants with extensive genetic data linked to physical measurements, health records, family history, and lifestyle information⁷. The recent release of whole-exome sequencing (WES) data now enables the exploration of rare variants for a variety of human traits and diseases and drug targets^{8,9}, including IOP and glaucoma. Rare variants can have large effect sizes and have demonstrated greater translational potential, e.g., *PCSK9*^{10,11}. These WES variants are also easier to interpret because they directly map to genes.

Using WES data from 454,756 participants in UKB, we conducted an exome-wide association study (ExWAS) to identify rare variants and genes associated with IOP, evaluate their effects on glaucoma in UKB and the FinnGen cohort, and explore potential drug targets of the identified genes. We also constructed a rare-variant polygenic risk score (rvPRS) and tested its association with glaucoma. To the

best of our knowledge, this study represents the largest rare-variant study of IOP to date. Our results uncovered rare variants regulating IOP, and subsequently, furthered our understanding of the biological mechanisms of IOP and potential drug targets for managing glaucoma.

Results

We identified 14 rare variants (11 of which are novel) significantly associated with IOP, among which six were identified in white-only analysis and seven additional ones were identified in pan-ancestry analysis. Table 1 displays the single-variant association results. Our top SNP, rs74315329 ($P = 1.22 \times 10^{-26}$) is a well-known stop-gain variant in *MYOC*, the first gene identified for primary open-angle glaucoma (POAG)¹². Consistently, rs28991009 in *ANGPTL7* previously identified in our array-based GWAS² shows significance in this ExWAS using WES data. In white-only results, rs37278669, a nonsynonymous variant (minor allele frequency [MAF] = 0.011%), in *BODILI*, shows a significant association with IOP ($P = 5.75 \times 10^{-9}$, beta = 4.08) in UKB. *BODILI* is also significantly associated with the FinnGen phenotype “use of antiglaucoma preparations and miotics” ($P = 5.10 \times 10^{-6}$). The start-loss variant, rs753877638, in *ACAD10* is significantly associated with both IOP ($P = 1.30 \times 10^{-10}$, beta = 8.41, MAF = 0.003%) and glaucoma ($P = 3.68 \times 10^{-4}$) in UKB. In pan-ancestry analysis, rs201956837 in *HLA-B* is associated with IOP ($P = 8.65 \times 10^{-9}$, beta = 4.37, MAF = 0.008%). Despite rs201956837 being an intronic variant, the gene *HLA-B* is highly associated with glaucoma in FinnGen ($P = 1.10 \times 10^{-9}$). A Manhattan plot of the genome-wide p-values for pan-ancestry results is shown in Figure 1 (a). The genomic control lambda for white-only and pan-ancestry analyses are 1.01 and 1.02, respectively, which are well under control. The corresponding quantile-quantile plots are shown in Supplementary Figure S1.

From SAIGE-GENE analysis, 35 additional genes showed significant associations with IOP and 31 of which are novel, among which 11 were identified from white-only analysis and 20 additional ones were identified from pan-ancestry analysis. Table 2 displays the gene-based association results. A Manhattan plot of the genome-wide p-values for pan-ancestry results is shown in Figure 1 (b). Rare variants in

previously known IOP genes, *MTOR*², *EVA1C*¹³, and *CFAP298-TCP10L*¹³, identified from common-variant investigations show significant gene-based associations with $P = 1.08 \times 10^{-12}$, $P = 9.51 \times 10^{-10}$, and $P = 1.34 \times 10^{-8}$, respectively. Several of these ExWAS significant IOP genes, such as *PTPRB*, *KIF21A*, *DNTT*, also show a significant association with glaucoma in UKB with $P = 3.26 \times 10^{-5}$, 0.009, 0.007, respectively. Many of these IOP genes are associated with glaucoma-related traits in FinnGen. For example, *PTPRB* is associated with glaucoma-related operations ($P = 1.7 \times 10^{-5}$), and *SYNGR3* and *ZNF598* are associated with use of antiglaucoma preparations and miotics ($P = 4.20 \times 10^{-5}$). *UBN1* is associated with juvenile open-angle glaucoma ($P = 1.8 \times 10^{-5}$). *RPL10A* and *TEAD3* are associated with exfoliation glaucoma ($P = 9.9 \times 10^{-6}$). *TAF1B* is associated with primary angle-closure glaucoma ($P = 1.90 \times 10^{-5}$). *ISY1-RAB43* is associated with normotensive glaucoma. *DOK4* is associated with glaucoma suspect ($P = 3.20 \times 10^{-5}$). *RHOC*, *PPM1J* and *LCE1F* are associated with glaucoma ($P < 5 \times 10^{-5}$). Notably, *ADRB1*, *PTPRB*, *RPL26*, *RPL10A*, *EGLN2*, and *MTOR* also have existing drug targets.

Table 3 displays the current known and proposed drug targets for these IOP rare-variant genes, such as *ADRB1* (adrenoceptor beta 1), which is a known drug target for topical beta-adrenergic receptor antagonists, or beta-blockers, known to lower IOP. To the best of our knowledge, our results provided the first reported evidence for the association between IOP and *ADRB1*. *ADRB1* is expressed in human trabecular meshwork and ciliary body¹⁴, as well as cardiac tissue (Supplementary Figure S2). Glaucoma drugs targeting *ADRB1* include topical beta-blockers, such as timolol, betaxolol, carteolol, levobunolol, levobetaxolol, and metipranolol. Two older, outdated glaucoma medications include the adrenergic agonists, dipivefrin and epinephrine. In addition, several of these drugs are also used in treating hypertension and cardiovascular disease. *PTPRB* is highly expressed in the vein and artery endothelium cells (Supplementary Figure S2). It is a proposed drug target for retinal vein occlusion, diabetic retinopathy and diabetic macular edema. Razuprotafib is a small molecule targeting *PTPRB* that acts as a negative regulator of Tie2 in diseased vascular endothelium by receptor-type tyrosine-protein phosphatase beta inhibition. *EGLN2*, a neighboring gene from the readthrough gene *RAB4B-EGLN2*, has drug trials

for roxadustat, daprodustat, and vadadustat, which inhibit a hypoxia-inducible factor prolyl hydroxylase. These drugs target anemia and chronic kidney disease. *MTOR* is targeted by perhexiline, a drug used for cardiovascular disease that inhibits the serine/threonine-protein kinase mTOR. The *MTOR* gene is highly expressed in microvessel endothelium cells throughout the eye (Supplementary Figure S2). *RPL26* and *RPL10A* have three experimental drugs, i.e., ataluren, ELX-02, and MT-3724, two of which (ataluren and ELX-02) work as 80S ribosome modulators while MT-3724 functions as an 80S inhibitor. These drugs are in development for various diseases, such as cystic fibrosis, muscular dystrophy, hemophilia, epilepsy, kidney disease, and leukemia.

We further constructed a rare-variant polygenic risk score (rvPRS) using the IOP rare variants with $P < 5 \times 10^{-8}$ from pan-ancestry analysis (Supplementary Table S1), excluding *MYOC* due to its known large effect on glaucoma, and tested its association with glaucoma in independent UKB European subjects, who did not participate in the IOP measurements. This rvPRS is significantly associated with glaucoma with $P = 1.02 \times 10^{-6}$, indicating the relevance of these IOP rare variants in glaucoma. When we used the rare variants identified from white-only subjects, the rvPRS yielded a much-mitigated association with glaucoma with $P = 6.42 \times 10^{-4}$.

Discussion

In this study, we conducted the largest ExWAS of IOP to date using data from UKB. By employing single-variant and gene-based analyses, two complementary frameworks, we have expanded our knowledge of the genetic architecture of IOP, especially of the role of rare variants, beyond previous studies involving microarray data, which mainly covered common variants. In addition to confirming known IOP genes, we identified 40 novel genes for IOP, demonstrating the power of including and aggregating rare variants in gene discovery. Many of these IOP genes are also associated with glaucoma phenotypes in UKB and FinnGen. Six of these genes are drug targets that are either established for

clinical treatment or in clinical trials. Furthermore, we constructed a rvPRS and showed its significant association with glaucoma in independent subjects.

We also showed that including subjects of all ancestries in a pan-ancestry analysis further improved the statistical power to identify rare variants. It was evident that pan-ancestry analyses identified additional rare variants and genes beyond white-only analyses in both single-variant and gene-based analyses.

Testing these IOP variants and genes for their effects in glaucoma-related traits in both UKB and FinnGen and querying for drug targets further increased their translational relevance. Furthermore, the IOP rvPRS constructed using the rare variants identified from pan-ancestry analysis showed an even stronger association signal with glaucoma in independent white subjects than using white-only rare variants.

A concern with multi-ancestry datasets is false-positive signals. Numerous previous GWAS used European subjects only. In some studies, it was further reduced to unrelated European subjects. One way to analyze multi-ethnic GWAS datasets is using meta-analysis^{1,15}, which is typically used for dealing with common variants. However, rare variants may not have enough carriers in individual ancestral groups, resulting in too few carriers to be analyzed. A pooled approach is an attractive alternative for combining ancestrally diverse populations¹⁶, especially for rare variants. Recent advances in statistical genetics tools also made this possible. For example, REGENIE¹⁷, a machine learning approach, can avoid the parameter inflation in ultra-rare-variant situations while controlling for both population stratification and sample relatedness. SAIGE¹⁸ uses mixed-effects models to adjust for both population stratification and genetic relationship matrix. Using these state-of-the-art methods, we showed the effectiveness of including non-European subjects in pan-ancestry analyses to further increase the study power. With advanced statistical genetics tools that can adjust for both genetic relatedness, principal components (PCs) of genetic ancestry and ancestral clusters, it is feasible to carry out pan-ancestry analyses in a pooled/combined approach. Further research is still necessary to maximize the power of pan-ancestry analysis¹⁶.

Genetics provides vital information to identify drug targets. The generation of this WES data is sponsored by eight pharmaceutical companies, including Regeneron and AstraZeneca⁹, which clearly shows the value of this dataset to that industry. Drug candidates that have genetics support are twice as likely to be successful than those without genetics support¹⁹. Six genes, i.e., *ADRB1*, *PTPRB*, *RPL26*, *RPL10A*, *EGLN2*, and *MTOR*, out of our gene-based analyses have existing therapeutic molecular targets. The most notable one, *ADRB1*, is the target of cardiovascular and glaucoma drugs, which include the broad class of glaucoma drugs targeting the beta-adrenergic receptor antagonists. For example, Timolol was a first-line drug for lowering IOP by blocking the beta-adrenergic receptors in the ciliary body²⁰ to decrease aqueous humor flow²¹. More recently, timolol has been shown to have an effect on outflow facility²², which also impacts IOP. The other five genes are targets in many clinical trials involving razuprotafib, ataluren, ELX-02, MT-3724, roxadustat, daprodustat, vadadustat, and perhexiline, which provide candidates for drug repurposing for possible glaucoma treatment. For example, razuprotafib has been shown recently as an adjunct to latanoprost for treating glaucoma patients²³. Razuprotafib also appears to stabilize blood vessels²³. Roxadustat has proposed pathways affecting blood cell production²⁴. Taken together, many of these drugs appear to be involved with cardiovascular disease and blood flow. Additionally, genome-wide associations of the identified genes showed numerous significant associations with vascular-related phenotypes (Supplementary Table S2). This relationship indicates that it may be possible to repurpose certain drugs that work on cardiovascular disease for glaucoma.

This study is not without limitations. Rare variants have their intrinsic challenges. The rarity of these variants makes their replication far more difficult than common variants. Nevertheless, since IOP is an endophenotype of glaucoma and ~70% glaucoma GWAS hits are also associated with IOP¹⁵, it is reasonable to test these IOP hits for their glaucoma effects⁴ although it should not be assumed that all IOP hits are associated with glaucoma. Furthermore, IOP hits can also provide translation implications for glaucoma management since lowering IOP is currently the sole proven solution for glaucoma treatment. Hence, we checked the significance of these IOP variants and genes on glaucoma-related traits in both

UKB and FinnGen cohorts. In UKB, a combination of self-reported glaucoma and ICD-10/9 codes for glaucoma phenotypes is not homogeneous for specialized glaucoma subtypes, but previous studies have demonstrated the effect of using it for studying primary open-angle glaucoma genetics^{4,25}. Despite being the largest WES data currently available, diversity is still low, and European subjects comprise about 94% of the UKB cohort. Other larger ancestral groups are no doubt invaluable and can provide further information for discovery and validation. About half of the IOP rare-variant genes identified were found to be associated with glaucoma-related traits in either UKB or FinnGen. Further studies are required to confirm the remaining ones for their impacts on glaucoma. Furthermore, the best approach for analyzing datasets of ancestrally diverse populations remains an ongoing research topic¹⁶, especially for rare variants.

In conclusion, we carried out the largest ExWAS of IOP to date. In addition to showing the efficacy of single-variant and white-only analyses, our study clearly supports using gene-based aggregation and pan-ancestry analyses to further increase the study power. We demonstrated the value of rare variants to enhance our understanding of the biological mechanisms regulating this trait, and uncovered potential novel therapeutic targets for glaucoma.

Materials and Methods

UKB Resource

UKB is an ongoing large prospective cohort study. Details regarding this cohort have been described elsewhere^{26,27}. Briefly, the UKB recruited over 500,000 adult participants (40 to 70 years of age at enrollment) living in the United Kingdom who were registered with the National Health Service at the study baseline (from 2006 to 2010). Medical information (self-report and electronic health records), family history, lifestyle information, as well as DNA samples, were collected. Ophthalmological data were also collected for a subset of study participants (~118,000). Most participants (~94%) reported their

ethnic background as white and the rest originated outside of Europe⁷. Our access to the resource was approved by UKB and we obtained access to fully de-identified data.

FinnGen Resource

The FinnGen study is a large biobank study focused on the population of Finland²⁸. Over 200,000 participants have been enrolled, genotyped and phenotyped. 500,000 participants are projected to be enrolled by the end of 2023. The study aims to show the power of nationwide biobanks, electronic health records and an isolated population in identifying rare variants associated with different diseases. Data was collected from different Finnish biobanks and digital health care data on Finland citizens starting in 2017. The recruited population has an age average of 63 years and hospital-based recruitment predominates thus far. Phenotypes were built using the International Classification of Disease Ninth and Tenth Revision (ICD-9 and ICD-10) codes. Genotyping was done with a custom Axiom FinnGen1 and legacy arrays and further imputed to 17 million markers based on whole-genome sequences of Finns. Out of 2,861 endpoint phenotypes created for this study, 15 are glaucoma related (Supplementary Table S3): neovascular glaucoma, primary angle-closure glaucoma, other and unspecified glaucoma, glaucoma, use of antiglaucoma preparations and miotics, juvenile open-angle glaucoma, normotensive glaucoma, glaucoma-related operations, primary open-angle glaucoma (strict), glaucoma (exfoliation), primary open-angle glaucoma, glaucoma secondary to other eye disorders, glaucoma secondary to eye inflammation, glaucoma secondary to eye trauma, and glaucoma suspect. The study used the SAIGE mixed models for their association analyses. The summary statistics are publicly online available (see web resources).

UKB WES and Quality Control

WES for all UKB participants were generated at the Regeneron Genetic Center^{8,9}. The sequencing, variant calling, and quality control were detailed previously^{8,29}. Briefly, sequencing was done on the Illumina NovaSeq 6000 platform using 75 base pair paired-end reads. Variant calling and quality control

were performed using the SPB protocol³⁰. The high-quality WES data have been reported to exceed 20x coverage at 95.8% of targeted bases. We overlapped the data with participants who participated in the ophthalmological measurements and kept all samples that had missing rate < 2.5%. We kept autosomal variants with call rate > 95% and minor allele count (MAC) ≥ 1 (15.1 million). We annotated these variants using VEP² and annovar³¹.

IOP Measurements in UKB

IOP measurements were obtained using the Optical Response Analyzer (Reichert Corp., Philadelphia, PA) and have been described previously³². In brief, both corneal-compensated and Goldman-correlated IOP measurements were collected. We used corneal-compensated IOP for this study since it is less affected by corneal thickness^{33,34}. The average of both eyes was used for downstream analysis. If only one IOP measurement was obtained, it was used as the final value. Study participants who received eye surgery within 4 weeks prior to the ocular assessment or those with possible eye infections did not receive IOP measurements. Moreover, we excluded study participants with extreme values of IOP, i.e., in the bottom and top 0.3 percentiles, and outliers, including subjects who had either eye surgery or used eye drop medications^{2,35}. Overlapping with the WES data, 98,674 white subjects and 110,260 pan-ancestry (all ancestry combined) subjects remained.

Single-variant and gene-based ExWAS analyses

We performed single-variant association analyses using a machine-learning method implemented by REGENIE¹⁷, accounting for population stratification and sample relatedness. We analyzed all variants with MAC ≥ 5 (REGENIE default) and included age, sex, and the first 10 PCs as covariates. Genetic variants with $P < 1 \times 10^{-8}$ were declared ExWAS significant³⁶. In addition to using European subjects, recent ExWAS studies advocate to include subjects of all ancestries^{37,38}. Hence, we performed both white only and pan-ancestry analyses (added an additional covariate for four major ancestral groups, i.e., European, South Asian, East Asian, and African, identified by the K-Means clustering algorithm).

For gene-based association tests, we used SAIGE-GENE¹⁸, a generalized mixed model approach that can adjust for both population stratification and genetic relationship. It performs rare-variant collapsing/aggregation tests, such as SKAT-O³⁹, burden⁴⁰ and SKAT^{41,42}. We used predicted loss of function (pLOF) variants as the variants for gene sets. We defined pLOF variants as: stop gained, stop lost, start lost, splice donor, splice acceptor and frameshift based on the VEP⁴³ annotation and gnomAD pLOF variants⁴⁴. We included age, sex, and the first 10 PCs as covariates. Genes with $P < 2.5 \times 10^{-6}$ were declared significant. We performed both white-only and pan-ancestry analyses (further added dummy variables for the major ancestral groups to the covariates).

Glaucoma lookup in UKB and FinnGen

Since lowering IOP is currently the only glaucoma treatment, we performed a lookup in glaucoma traits in UKB and FinnGen resources for all ExWAS significant IOP rare variants and genes. In the UKB subjects, glaucoma cases were identified if they self-reported glaucoma (UKB data fields 6148, 20002) or had an ICD-10 or ICD-9 diagnosis code for glaucoma (UKB data fields 131186, 131188, 41202, 41204, 41076, 41078, 41270), excluding glaucoma secondary to eye trauma, secondary to eye inflammation, secondary to other eye disorders, secondary to drugs, and other glaucoma. The selection of glaucoma based on self-reports and ICD-10 codes has been shown to be effective in previous studies^{4,25}.

Furthermore, the proportion of non-POAG cases in UKB was expected to be small⁴⁵. Controls were identified as those who did not have glaucoma or self-reported eye problems. Overlapping with WES data, 14,378 white cases and 409,571 white controls, 15,606 pan-ancestry cases and 437,417 pan-ancestry controls remained. We further checked our top IOP genes in the FinnGen GWAS summary statistics²⁸ by querying each of them in their online results (see web resources). For checking broader phenome-wide associations, we used PheWeb⁴⁶.

Drug Targets Prioritization

To prioritize drug targets for the identified rare-variant genes, we used the Open Targets online resource.

For the identified genes, we queried the Open Targets for known drugs, their mechanisms of action (source ChEMBL), and disease information. The druggable genes provide key information on the relevance of these genes on IOP and glaucoma management and potential drugs for repurposing.

rvPRS

From the pan-ancestry single-variant association results, we selected rare variants with $P < 5 \times 10^{-8}$ excluding *MYOC*, the well-known rare-variant gene for glaucoma. Details of these variants are shown in the Supplementary Table S1. We then constructed a rvPRS using PLINK similar to our previous approach, which was calculated as the summation of the number of rare risk alleles, assuming each risk allele has the same effect³⁵. We then tested the association between the rvPRS and glaucoma in independent UKB white subjects (subjects who did not participate in the IOP measurements) using logistic regression adjusting for age and sex.

Acknowledgements

We would like to thank the study participants from the UK Biobank as well as the staff who aided in data collection and processing.

Conflict of Interest Statement

None declared.

Web Resources

The URLs for downloaded data and programs:

ANNOVAR, <http://annovar.openbioinformatics.org/>

ChEMBL, <https://www.ebi.ac.uk/chembl/>

FinnGen, <https://www.finngen.fi/>

Genevestigator, <https://genevestigator.com/>

PheWeb, <https://pheweb.sph.umich.edu/>

REGENIE, <https://rgcgithub.github.io/regenie/>

SAIGE, <https://github.com/weizhouUMICH/SAIGE>

UK Biobank, <https://www.ukbiobank.ac.uk>

VEP, <https://useast.ensembl.org/info/docs/tools/vep/index.html>

References

- 1 Choquet, H. *et al.* A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. *Nature communications* **8**, 2108, doi:10.1038/s41467-017-01913-6 (2017).
- 2 Gao, X. R., Huang, H., Nannini, D. R., Fan, F. & Kim, H. Genome-wide association analyses identify new loci influencing intraocular pressure. *Hum Mol Genet* **27**, 2205-2213, doi:10.1093/hmg/ddy111 (2018).
- 3 Khawaja, A. P. *et al.* Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. *Nat Genet* **50**, 778-782, doi:10.1038/s41588-018-0126-8 (2018).
- 4 MacGregor, S. *et al.* Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. *Nat Genet* **50**, 1067-1071, doi:10.1038/s41588-018-0176-y (2018).
- 5 Xu, Z., Hysi, P. & Khawaja, A. P. Genetic Determinants of Intraocular Pressure. *Annu Rev Vis Sci* **7**, 727-746, doi:10.1146/annurev-vision-031021-095225 (2021).
- 6 van Koolwijk, L. M. *et al.* Common genetic determinants of intraocular pressure and primary open-angle glaucoma. *PLoS Genet* **8**, e1002611, doi:10.1371/journal.pgen.1002611 (2012).
- 7 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 8 Szustakowski, J. D. *et al.* Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat Genet* **53**, 942-948, doi:10.1038/s41588-021-00885-0 (2021).
- 9 Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature* **599**, 628-634, doi:10.1038/s41586-021-04103-z (2021).
- 10 Dewey, F. E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science* **354**, doi:10.1126/science.aaf6814 (2016).
- 11 Abul-Husn, N. S. *et al.* Genetic identification of familial hypercholesterolemia within a single US health care system. *Science* **354**, doi:ARTN aaf7000 10.1126/science.aaf7000 (2016).
- 12 Stone, E. M. *et al.* Identification of a gene that causes primary open angle glaucoma. *Science* **275**, 668-670 (1997).
- 13 Han, X. *et al.* Association of Myopia and Intraocular Pressure With Retinal Detachment in European Descent Participants of the UK Biobank Cohort: A Mendelian Randomization Study. *JAMA ophthalmology* **138**, 671-678, doi:10.1001/jamaophthalmol.2020.1231 (2020).
- 14 Inagaki, Y. *et al.* Polymorphism of beta-adrenergic receptors and susceptibility to open-angle glaucoma. *Mol Vis* **12**, 673-680 (2006).
- 15 Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. *Nature communications* **12**, 1258, doi:10.1038/s41467-020-20851-4 (2021).
- 16 Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589-603, doi:10.1016/j.cell.2019.08.051 (2019).
- 17 Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* **53**, 1097-1103, doi:10.1038/s41588-021-00870-7 (2021).
- 18 Zhou, W. *et al.* Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. *Nat Genet* **52**, 634-639, doi:10.1038/s41588-020-0621-6 (2020).
- 19 Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications. *Nat Genet* **47**, 856-860, doi:10.1038/ng.3314 (2015).
- 20 Wax, M. B. & Molinoff, P. B. Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. *Invest Ophthalmol Vis Sci* **28**, 420-430 (1987).
- 21 Coakes, R. L. & Brubaker, R. F. The mechanism of timolol in lowering intraocular pressure. In the normal eye. *Arch Ophthalmol* **96**, 2045-2048 (1978).

- 22 Kazemi, A. *et al.* Effect of Timolol on Aqueous Humor Outflow Facility in Healthy Human Eyes. *Am J Ophthalmol* **202**, 126-132, doi:10.1016/j.ajo.2019.02.014 (2019).
- 23 Brigell, M., Withers, B., Buch, A. & Peters, K. G. Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension. *Transl Vis Sci Technol* **11**, 7, doi:10.1167/tvst.11.1.7 (2022).
- 24 Dhillon, S. Roxadustat: First Global Approval. *Drugs* **79**, 563-572, doi:10.1007/s40265-019-01077-1 (2019).
- 25 Craig, J. E. *et al.* Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. *Nat Genet* **52**, 160-166, doi:10.1038/s41588-019-0556-y (2020).
- 26 Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *Plos Med* **12**, doi:ARTN e1001779 10.1371/journal.pmed.1001779 (2015).
- 27 Allen, N. E., Sudlow, C., Peakman, T. & Collins, R. UK Biobank Data: Come and Get It. *Sci Transl Med* **6**, doi:ARTN 224ed4 10.1126/scitranslmed.3008601 (2014).
- 28 Kurki, M. I. *et al.* FinnGen: Unique genetic insights from combining isolated population and national health register data. *medRxiv*, 2022.2003.2003.22271360, doi:10.1101/2022.03.03.22271360 (2022).
- 29 Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank exomes. *Nature* **597**, 527-532, doi:10.1038/s41586-021-03855-y (2021).
- 30 Van Hout, C. V. *et al.* Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature* **586**, 749-756, doi:10.1038/s41586-020-2853-0 (2020).
- 31 Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* **38**, e164, doi:10.1093/nar/gkq603 (2010).
- 32 Chua, S. Y. L. *et al.* Cohort profile: design and methods in the eye and vision consortium of UK Biobank. *BMJ Open* **9**, e025077, doi:10.1136/bmjopen-2018-025077 (2019).
- 33 Wasielica-Poslednik, J., Berisha, F., Aliyeva, S., Pfeiffer, N. & Hoffmann, E. M. Reproducibility of ocular response analyzer measurements and their correlation with central corneal thickness. *Graefes Arch Clin Exp Ophthalmol* **248**, 1617-1622, doi:10.1007/s00417-010-1471-1 (2010).
- 34 Zimmermann, M., Pitz, S., Schmidtman, I., Pfeiffer, N. & Wasielica-Poslednik, J. Tonographic Effect of Ocular Response Analyzer in Comparison to Goldmann Applanation Tonometry. *PLoS One* **12**, e0169438, doi:10.1371/journal.pone.0169438 (2017).
- 35 Gao, X. R., Huang, H. & Kim, H. Polygenic Risk Score Is Associated With Intraocular Pressure and Improves Glaucoma Prediction in the UK Biobank Cohort. *Transl Vis Sci Technol* **8**, 10, doi:10.1167/tvst.8.2.10 (2019).
- 36 Fadista, J., Manning, A. K., Florez, J. C. & Groop, L. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. *Eur J Hum Genet* **24**, 1202-1205, doi:10.1038/ejhg.2015.269 (2016).
- 37 Curtis, D. Analysis of 200,000 Exome-Sequenced UK Biobank Subjects Implicates Genes Involved in Increased and Decreased Risk of Hypertension. *Pulse (Basel)* **9**, 17-29, doi:10.1159/000517419 (2021).
- 38 Nag, A. *et al.* Assessing the contribution of rare-to-common protein-coding variants to circulating metabolic biomarker levels via 412,394 UK Biobank exome sequences. *medRxiv*, 2021.2012.2024.21268381, doi:10.1101/2021.12.24.21268381 (2021).
- 39 Lee, S., Wu, M. C. & Lin, X. Optimal tests for rare variant effects in sequencing association studies. *Biostatistics (Oxford, England)* **13**, 762-775, doi:10.1093/biostatistics/kxs014 (2012).
- 40 Li, B. & Leal, S. M. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet* **83**, 311-321, doi:S0002-9297(08)00408-4 [pii] 10.1016/j.ajhg.2008.06.024 (2008).
- 41 Wu, M. C. *et al.* Powerful SNP-set analysis for case-control genome-wide association studies. *Am J Hum Genet* **86**, 929-942, doi:10.1016/j.ajhg.2010.05.002 (2010).

- 42 Wu, M. C. *et al.* Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet* **89**, 82-93, doi:S0002-9297(11)00222-9 [pii] 10.1016/j.ajhg.2011.05.029 (2011).
- 43 McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122, doi:10.1186/s13059-016-0974-4 (2016).
- 44 Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434-443, doi:10.1038/s41586-020-2308-7 (2020).
- 45 Chan, M. P. Y. *et al.* Glaucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study. *BMJ* **358**, j3889, doi:10.1136/bmj.j3889 (2017).
- 46 Gagliano Taliun, S. A. *et al.* Exploring and visualizing large-scale genetic associations by using PheWeb. *Nat Genet* **52**, 550-552, doi:10.1038/s41588-020-0622-5 (2020).

Figure Legend

Figure 1. Manhattan plots displaying the $-\log_{10}(P)$ for the association between IOP and rare variants and genes.

(a) Single-variant pan-ancestry results. The dotted horizontal line represents exome-wide significance associations ($P < 1 \times 10^{-8}$). (b) Gene-based pan-ancestry results. The dotted horizontal line represents gene-based significance associations ($P < 2.5 \times 10^{-6}$). Genetic variants or genes are plotted by genomic position.

Table 1. Exome-wide significant rare variants for intraocular pressure

	Chr	Pos	rsID	A0	A1	A1 Freq	Beta	P	Gene	Function	UKB	FinnGen	
											P_G	Top P_G	Glaucoma phenotype
White	1	11193627	rs28991009	G	T	0.796%	-0.53	1.19E-10	<i>ANGPTL7</i>	nonsynonymous	2.09E-06	7.80E-17	Glaucoma
	1	171636338	rs74315329	G	A	0.134%	2.12	1.22E-26	<i>MYOC</i>	stop gain	1.01E-37	2.30E-24	Glaucoma
	4	13613559	rs372786669	T	C	0.011%	4.08	5.75E-09	<i>BODIL1</i>	nonsynonymous	0.073	5.10E-06	Use of antiglaucoma preparations and miotics
	8	84887679	rs371413262	C	T	0.003%	7.73	3.66E-09	<i>RALYL</i>	nonsynonymous	0.350	1.10E-04	Glaucoma exfoliation
	10	86687010	rs112082622	C	T	0.003%	8.62	1.83E-09	<i>LDB3</i>	intronic	0.448	1.90E-04	Use of antiglaucoma preparations and miotics
	12	111692710	rs753877638	A	G	0.003%	8.41	1.30E-10	<i>ACAD10</i>	start loss	3.68E-04	2.30E-04	Glaucoma suspect
Pan-ancestry (additional hits)	1	1708342	rs556417493	C	G	0.003%	6.55	8.67E-09	<i>CDK11A</i>	intronic	0.023	7.60E-05	Juvenile Open-Angle Glaucoma
	1	244432616	rs375507039	T	C	0.003%	7.69	5.00E-09	<i>ADSS2</i>	intronic	0.016	5.90E-05	Use of antiglaucoma preparations and miotics
	6	31356961	rs201956837	G	A	0.008%	4.37	8.65E-09	<i>HLA-B</i>	intronic	0.666	1.10E-09	Glaucoma
	10	73911900	rs367716060	C	A	0.002%	8.27	8.77E-09	<i>PLAU</i>	nonsynonymous	0.006	2.70E-04	Glaucoma suspect
	10	79349655	rs557881342	C	T	0.003%	7.60	7.03E-09	<i>PPIF</i>	intronic	0.693	1.70E-04	Primary open-angle glaucoma
	14	72670683	rs933632776	AC	A	0.002%	8.99	3.92E-10	<i>DPF3</i>	UTR3	0.309	1.50E-05	Glaucoma
	19	1529427	rs776910868	G	T	0.004%	6.93	1.09E-09	<i>PLK5</i>	nonsynonymous	0.176	1.50E-05	Other and unspecified glaucoma

Variants with $P < 1 \times 10^{-8}$ are presented. Their corresponding association results for glaucoma in UK Biobank and FinnGen are also shown. The upper panel shows white-only significant results. The bottom panel shows additional hits from pan-ancestry analysis. Gene name is in boldface if it has not been previously reported for intraocular pressure. Genomic positions are according to hg38. Chr, chromosome; Pos, position; A0, allele 0; A1, allele 1; P_G , p-values for glaucoma in UK Biobank and glaucoma-related traits in FinnGen.

Table 2. Genome-wide significant results for intraocular pressure from gene-based analysis

	Chr	Pos	Gene	<i>P</i>	UKB	FinnGen	
					<i>P_G</i>	Top <i>P_G</i>	Glaucoma phenotype
White	1	11106534-11273497	<i>MTOR</i>	1.08E-12	1.03E-05	7.80E-17	Glaucoma
	1	11189323-11195981	<i>ANGPTL7</i>	4.59E-13	1.95E-06	7.80E-17	Glaucoma
	1	37692515-37709719	<i>CDCA8</i>	1.13E-06	0.176	5.90E-06	Glaucoma
	1	171635416-171652688	<i>MYOC</i>	2.06E-25	3.22E-36	2.30E-24	Glaucoma
	1	183471992-183554193	<i>SMG7</i>	1.37E-06	0.310	2.40E-04	Primary open-angle glaucoma
	4	47847232-47914667	<i>NFXL1</i>	7.34E-07	0.028	7.80E-04	Juvenile open-angle glaucoma
	6	31353874-31357179	<i>HLA-B</i>	1.24E-06	0.394	1.10E-09	Glaucoma
	6	31355223-31355316	<i>MIR6891</i>	1.33E-07	0.318	-	-
	10	114043865-114046904	<i>ADRB1</i>	1.16E-06	0.085	3.50E-04	Primary open-angle glaucoma, strict
	12	39293227-39443147	<i>KIF21A</i>	7.31E-07	0.009	5.70E-04	Primary angle-closure glaucoma
	12	70515869-70637440	<i>PTPRB</i>	2.80E-07	3.26E-05	1.70E-05	Glaucoma-related operations
	16	57471921-57487139	<i>DOK4</i>	4.01E-07	0.859	3.20E-05	Glaucoma suspect
	17	8377515-8383193	<i>RPL26</i>	2.18E-06	0.770	7.90E-05	Glaucoma, exfoliation
	19	40778218-40808441	<i>RAB4B-EGLN2</i>	1.93E-06	0.361	8.60E-05	Normotensive glaucoma
	Pan-ancestry (additional hits)	1	91260765-91408008	<i>HFMI</i>	1.20E-06	0.535	3.50E-04
1		112701126-112707403	<i>RHOC</i>	1.36E-07	0.454	2.10E-05	Glaucoma
1		112709993-112715328	<i>PPMIJ</i>	6.82E-09	0.796	2.10E-05	Glaucoma
1		152776371-152776969	<i>LCE1F</i>	8.35E-07	0.388	6.80E-06	Glaucoma
2		9843441-9934416	<i>TAF1B</i>	5.95E-07	0.634	1.90E-05	Primary angle-closure glaucoma
2		69457996-69643739	<i>AAK1</i>	3.06E-07	0.085	3.80E-06	Glaucoma secondary to other eye disorders
3		100749328-100993508	<i>ABI3BP</i>	1.61E-06	0.221	1.90E-05	Primary open angle glaucoma
3		129087568-129161230	<i>ISY1-RAB43</i>	2.19E-07	1.000	2.30E-05	Normotensive glaucoma
5		73446265-73448777	<i>FOXD1</i>	1.43E-07	0.153	9.00E-05	Primary angle-closure glaucoma
6		35468400-35470781	<i>RPL10A</i>	2.89E-07	0.031	9.90E-06	Glaucoma, exfoliation
6	35473596-35497079	<i>TEAD3</i>	2.84E-07	0.033	9.90E-06	Glaucoma, exfoliation	

7	65865771-65959558	VKORC1L1	6.72E-08	0.023	1.80E-04	Glaucoma suspect
7	65960683-65982230	GUSB	1.82E-06	0.061	1.90E-04	Glaucoma secondary to eye inflammation
9	137619000-137836127	EHMT1	1.77E-06	0.634	4.80E-04	Glaucoma
10	96304433- 96338564	DNTT	1.99E-06	0.007	1.00E-04	Glaucoma, exfoliation
14	50117129-50231578	SOS2	2.13E-09	0.806	1.60E-04	Juvenile open-angle glaucoma
14	94110735-94116690	IFI27	2.02E-06	0.602	1.10E-04	Primary open-angle glaucoma
16	1989969-1994275	SYNGR3	1.93E-06	0.688	4.20E-05	Use of antiglaucoma preparations and miotics
16	1997653-2009821	ZNF598	1.14E-06	0.796	4.20E-05	Use of antiglaucoma preparations and miotics
16	4846664-4882401	UBN1	6.05E-07	0.617	1.80E-05	Juvenile open-angle glaucoma
19	46647550-46661182	DACT3	1.54E-08	0.725	3.00E-04	Glaucoma suspect
21	32411691-32515387	EVA1C	9.51E-10	0.368	1.30E-04	Primary open-angle glaucoma
21	33935802-33984687	CFAP298-TCP10L	1.34E-08	1.000	1.30E-04	Primary open-angle glaucoma

Genes with $P < 2.5 \times 10^{-6}$ are presented. Their corresponding association results for glaucoma in UK Biobank and FinnGen are also shown. The upper panel shows white-only significant results. The bottom panel shows additional hits from pan-ancestry analysis. Gene name is in boldface if it has not been previously reported for intraocular pressure. Genomic positions are according to hg38. Chr, chromosome; Pos, position; P_G , p-values for glaucoma in UK Biobank and glaucoma-related traits in FinnGen.

Table 3. Known drug targets for the identified intraocular pressure rare-variant genes.

Gene	Known drugs	Mechanism of action	Disease information (including those in clinical trials)
<i>ADRB1</i>	CARTEOLOL HYDROCHLORIDE*	Beta-adrenergic receptor antagonist	Open-angle glaucoma
	TIMOLOL*	Beta-adrenergic receptor antagonist	Ocular hypertension, low tension glaucoma, cardiovascular disease, glaucoma, hemangioma, open-angle glaucoma, eye disease, corneal edema, portal hypertension, exfoliation syndrome, migraine disorder, varicose disorder, wet macular degeneration, hereditary hemorrhagic telangiectasia, diabetic macular edema, anterior ischemic optic neuropathy
	BETAXOLOL HYDROCHLORIDE*	Beta-1 adrenergic receptor antagonist	Open-angle glaucoma, hypertension, ocular hypertension
	TIMOLOL MALEATE*	Beta-1 adrenergic receptor antagonist	Glaucoma, ocular hypertension, hemangioma, open-angle glaucoma, corneal-edema, portal hypertension, ocular hypertension, anterior ischemic optic neuropathy
	CARTEOLOL	Adrenergic receptor beta antagonist	Glaucoma, cardiovascular disease, open-angle glaucoma
	DIPIVEFRIN*	Adrenergic receptor agonist	Glaucoma (no longer available)
	LEVOBETAXOLOL HYDROCHLORIDE*	Beta-1 adrenergic receptor antagonist	Glaucoma, ocular hypertension
	EPINEPHRINE*	Adrenergic receptor agonist	Glaucoma (no longer available)
	BETAXOLOL	Beta-1 adrenergic receptor antagonist	Hypertension, cardiovascular disease, open-angle glaucoma, ocular hypertension
	METIPRANOLOL	Beta-1 adrenergic receptor antagonist	Glaucoma
	LEVOBUNOLOL	Beta-1 adrenergic receptor antagonist	Glaucoma
LEVOBETAXOLOL	Beta-1 adrenergic receptor antagonist	Glaucoma, ocular hypertension	
<i>PTPRB</i>	RAZUPROTAFOB	Receptor-type tyrosine-protein phosphatase beta inhibitor	Diabetic macular edema, non-proliferative diabetic retinopathy, retinal vein occlusion, glaucoma (Brigell <i>et al.</i> 2022)
<i>RPL26</i> <i>RPL10A</i>	ATALUREN	80S Ribosome modulator	Cystic fibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy, aniridia, disorder of amino acid and other organic acid metabolism, hemophilia B, hemophilia A, epilepsy
	ELX-02	80S Ribosome modulator	Genetic disorder, kidney disease, cystinosis, cystic fibrosis
	MT-3724	80S Ribosome inhibitor	Diffuse large B-cell lymphoma, non-Hodgkins lymphoma, lymphoid leukemia, chronic lymphocytic leukemia
<i>EGLN2</i>	ROXADUSTAT	Hypoxia-inducible factor prolyl	Chronic kidney disease, anemia, myelodysplastic syndrome, ST elevation myocardial

		hydroxylase inhibitor	infarction
	DAPRODUSTAT	Hypoxia-inducible factor prolyl hydroxylase inhibitor	Anemia, peripheral vascular disease
	VADADUSTAT	Hypoxia-inducible factor prolyl hydroxylase inhibitor	Anemia, chronic kidney disease
<i>MTOR</i> **	PERHEXILINE	Serine/threonine-protein kinase mTOR inhibitor	Cardiovascular disease, hypertrophic cardiomyopathy, diabetic cardiomyopathy, diastolic heart failure, heart failure
	PALOMID-529	Serine/threonine-protein kinase mTOR inhibitor	age-related macular degeneration


This table shows the existing drugs that target the intraocular pressure rare-variant genes identified.

*FDA approved treatment for glaucoma and/or ocular hypertension.

***MTOR* has many more drugs and diseases in clinical trials not listed totaling 24 drugs and 87 diseases.

Figure 1. Manhattan plots displaying the $-\log_{10}(P)$ for the association between IOP and rare variants and genes.

(a)



(b)

